about
The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsSpecific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavirCycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells.Biodiversity of organotin resistant Pseudomonas from west coast of India.Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirLong-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infectionMethods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyUpregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.Microglia-derived HIV Nef+ exosome impairment of the blood-brain barrier is treatable by nanomedicine-based delivery of Nef peptides.Molecular and phylogenetic analysis of a novel family of fibrinogen-related proteins from mosquito Aedes albopictus cell line.Antimicrobial activity of marine bacteria associated with sponges from the waters off the coast of South East India.The Membrane-Active Phytopeptide Cycloviolacin O2 Simultaneously Targets HIV-1-infected Cells and Infectious Viral Particles to Potentiate the Efficacy of Antiretroviral Drugs
P50
Q28087336-DADD5EF3-976F-4D21-A8BE-038EB39A435DQ28534049-80AB84C8-D6E7-459C-A37B-2DE1CD7F4CD5Q30352465-E054F937-C021-4FCF-87C9-234FBE00EC9CQ33264809-52C906CD-E990-4022-9B22-C2E6F292FF12Q33611816-9933A0B6-0F4B-4059-8CC9-B2952AB1CA3FQ33625213-B689C63E-2E5D-4C8B-A722-1D000EC11995Q34516015-F9A9A0B7-239D-48C3-AD2D-06237C7FDF69Q34639923-C5FCA5A2-E15A-46F7-860A-1DC554C7513EQ34728884-A93CFA52-62E7-4A27-A971-42894CB4FA14Q35677168-42F841E1-5119-4D61-AB56-4B524C71CA2CQ36603756-9D14F5B9-A37A-4B8A-A6B7-5CBE39C190FBQ36969787-3F91EED0-8A1C-4D69-A07B-2E0A8718310AQ37403269-0D75B5EA-7E5D-42D7-AA8B-1E6181C89F7CQ38814829-550DF809-E8BD-445E-A3BD-8A3843872720Q39950198-B344FECE-5570-4880-8C5A-7CCCE2EBF7B4Q51725791-1D89EE21-1B39-40F2-8561-AA74D466AC0DQ64090302-3FE3AD33-4520-4635-A995-5131474F2C1E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Upal Roy
@ast
Upal Roy
@en
Upal Roy
@es
Upal Roy
@nl
Upal Roy
@sl
type
label
Upal Roy
@ast
Upal Roy
@en
Upal Roy
@es
Upal Roy
@nl
Upal Roy
@sl
prefLabel
Upal Roy
@ast
Upal Roy
@en
Upal Roy
@es
Upal Roy
@nl
Upal Roy
@sl
P106
P31
P496
0000-0002-0325-567X